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OBJECTIVE—The objective of this study was to test if the
proportion of new-onset diabetic subjects with the HLA-DR3/
4-DQB1*0302 genotype is decreasing over time.
RESEARCH DESIGN AND METHODS—We analyzed HLA
class II genotype frequencies over time in two large populations
with type 1 diabetes diagnosed at #18 years of age. There were
4,075 subjects from the Type 1 Diabetes Genetics Consortium
(T1DGC) and 1,675 subjects from the Barbara Davis Center
(BDC).
RESULTS—Both T1DGC and BDC cohorts showed a decrease
of the highest-risk HLA-DR3/4-DQB1*0302 genotype over time.
This decrease was greatest over time in T1DGC subjects with
age of onset #5 years (P 5 0.004) and onset between ages 6
and 10 years (P 5 0.002). The overall percent of HLA-DR3/4-
DQB1*0302 was greater in the T1DGC population compared with
the BDC population. There was an increased percent over time of
other HLA genotypes without HLA-DR3 or -DR4 in T1DGC new
onsets (P 5 0.003), and the trend was similar in BDC subjects
(P 5 0.08). Analyzing time trend, there appears to be a large
stepwise decrease in percent DR3/4 in the 1980s in T1DGC sub-
jects with onset age ,5 years (P 5 0.0001).
CONCLUSIONS—The change in frequency of multiple different
genotypes and a possible stepwise decrease in percent DR3/4
suggest a change in genetic risk factors and environmental
determinants of type 1 diabetes. Larger studies are needed to
conﬁrm the changing pattern of genetic risk because a stepwise
change may have direct bearing on deﬁning critical environmental
determinants of type 1 diabetes. Diabetes 60:1045–1049, 2011
T
he incidence of type 1 diabetes has been in-
creasing worldwide by approximately 3% per
year (1,2), with the highest increase occurring in
young children (3,4). The major type 1 diabetes
susceptibility locus maps to the HLA class II genes and
accounts for 30–50% of genetic type 1 diabetes risk (5,6).
Age at onset is inversely related to the frequency of high-
risk HLA genotypes, with young children having the
greatest proportion of HLA-DR3/4-DQB1*0302 genotype
(7,8). Although 40% of Caucasians in the U.S. have an HLA-
DR3 (with DQB1*0201) or -DR4 (with DQB1*0302) allele,
at least one of these alleles is present in 95% of patients
with type 1 diabetes. The estimated risk of developing type
1 diabetes for children in the general population who have
the HLA DR3-DQB1*0201/DR4-DQB1*0302 genotype is
;1:15–1:25 (9). Only 2.4% of the general population carries
this genotype compared with 30–40% of type 1 diabetic
patients. In siblings, HLA-DR3/4 heterozygosity identiﬁes
higher risk of type 1 diabetes than HLA identity (10). A
combination of HLA-DR3/4 heterozygosity and HLA iden-
tity in siblings is associated with extreme diabetes risk of
55% by age 12 years in the Diabetes Autoimmunity Study in
the Young (DAISY) population (11).
However, as type 1 diabetes incidence increases, the
percentage of those cases with high-risk HLA genotype is
decreasing (12). A study from the U.K. (13) compared two
cohorts and found a decrease in the high-risk HLA-DR3/
4-DQB1*0302 genotype from 47% (Golden Years cohort
diagnosed more than 50 years ago) to 35% in the more
recently diagnosed cohort (between 1985–2002). Hermann
et al. (8) reported a similar decrease in high-risk HLA
genotypes over time (from 25 to 18%), although both of
these studies (8,13) compared contemporary subjects with
selective cohorts of surviving adults with childhood-onset
type 1 diabetes. A study from Australia by Fourlanos et al.
(14) with continuous information available reports a de-
crease in the high-risk HLA genotype from 79% in 1950–
1969 to 28% in 2000–2005 in 462 subjects diagnosed before
age 18 years; the authors conclude that the rising in-
cidence of type 1 diabetes in childhood is accounted for by
cases with lower-risk HLA genotypes.
In this study, we analyze HLA class II allele frequencies
over a time period ranging from 1965 to 2008 in two large
populations of type 1 diabetic subjects diagnosed at age
#18 years and describe a possible stepwise decrease in
percent DR3/4.
RESEARCH DESIGN AND METHODS
The Type 1 Diabetes Genetics Consortium (T1DGC) has created a resource
base of well-characterized families from multiple ethnic groups in order to
facilitate the localization and characterization of type 1 diabetes susceptibility
genes (http://www.t1dgc.org). The T1DGC has recruited families consisting
mainly of nuclear families with an affected sib pair. In this study, we analyzed
4,075 subjects diagnosed between 1965 and 2006 with onset age #18 years
and complete HLA information available. The majority of the subjects were
Caucasian (93.6%), and there were no sex differences (male/female 5 51%).
The mean age of onset was 8.4 years (range: 6 months to 18 years).
Subjects from the Barbara Davis Center (BDC) diagnosed between 1965 and
2008 with age of onset #18 years and positive islet autoantibodies were in-
cluded (n 5 1,675). For subjects diagnosed before 1995, ICA512 and GAD65
antibodies were measured and available (on samples not obtained at time of
onset), and ICA512, GAD65, ZnT8 antibodies, and insulin autoantibody within
10 days of diagnosis were included for those diagnosed after 1995. The mean
age of onset was 9.2 years (range: 6 months to 18 years), and there were no
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BRIEF REPORTsex differences (male/female 5 52%). The majority of the subjects were
Caucasian (86.4%) with 4.8% Hispanic, 3.2% African American, and 5.6% other
ethnicity. The Colorado Multiple Institutional Review Board approved the
study protocol with informed consent.
Genotyping. HLA class II genotyping at the BDC was performed using se-
quence speciﬁc oligonucleotide (SSO) typing for DQA1 and DQB1 as described
previously (15) or real time PCR. For realtime PCR based typing, DNA was
isolated from whole blood using a Quickgene 610 L instrument (Autogen,
Holliston, MA). Seven Custom probes (Applied Biosystems, Foster City, CA)
and 10 primers (Integrated DNA Technologies, Coralville, IA) were used in 4
PCR wells. In addition, one Taqman premixed probe/primer mix was used in
one additional well (Applied Biosystems, Foster City, CA). The PCR was set up
in 5 wells per sample. In well 1, probes detected the presence or absence of
DR4, and in well 2, probes detected the presence or absence of DR3. Wells 3,
4, and 5 contained probes which detected the presence or absence of
DQB*0302 or DQB*0602.
SSO typing for DQA1 and DQB1 was done in the same way in the last few
years in both BDC and T1DGC populations as described previously (15,16).
Statistical analysis. Comparisons of genotype frequencies between the
2 cohorts over time were assessed by Fisher exact test or x
2 statistics. A P value
of 0.05 or less was considered to be statistically signiﬁcant. Genotype fre-
quencies were analyzed by decades for both T1DGC and BDC population as
well as by age of onset (ages #5, 6–10, and 11–18 years). HLA genotypes were
classiﬁed into the following groups: high-risk HLA-DR3/4-DQB1*0302; HLA-
DR4/4 and 4/X; HLA-DR3/3 and 3/X; HLA-DRX/X and protective HLA-DR2-
DQB1*0602 (where X is not DR3, DR4, or DQB1*0602). The protective
DRB1*0403 was removed from the DR4 category in the T1DGC population.
For T1DGC population, HLA-DR3/4-DQB1*0302 genotype was also analyzed in
2-year interval periods (4-year intervals before 1977 because of small numbers
during that period).
RESULTS
Both T1DGC and BDC cohorts showed a signiﬁcant de-
crease of the high-risk HLA-DR3/4-DQB1*0302 genotype
over time. In the T1DGC cohort, the frequency of the high-
risk HLA genotype decreased from 48% in 1965–1974 to
35% in 1995–2006 (Fig. 1A). In the BDC population, the
overall percent of HLA-DR3/4-DQB1*0302 was less than
in the T1DGC, but the difference over time was similar,
decreasing from 38% in 1965–1974 to 26% in 1995–2008
(Fig. 1B).
Decrease in high-risk HLA percentage was greatest over
time in T1DGC subjects with age of onset #10 years. In the
group diagnosed at age #5 years, the presence of HLA-
DR3/4-DQB1*0302 decreased from over 50% before 1985 to
39% in 1995–2006 (P 5 0.004). T1DGC subjects with onset
between ages 6 and 10 years had an even larger drop over
time in HLA-DR3/4-DQB1*0302 from 58 to 35% (P 5 0.002),
whereas subjects diagnosed after age 10 had a more
moderate decrease from 38 to 30% (P 5 0.005) (Fig. 2A).
High-risk HLA-DR3/4-DQB1*0302 genotype showed a sim-
ilar decrease in frequency over time in the BDC population,
although not all age groups had statistically signiﬁcant
differences, which was likely due to smaller numbers
(especially in the earlier decades). The percentage of
HLA-DR3/4-DQB1*0302 decreased from 48% in 1975–1984
to 36% in 1995–2008 for those diagnosed at age #5y e a r s
(P 5 0.70). The age 6–10 years onset group had a decrease
in HLA-DR3/4-DQB1*0302 from 36 to 22% (P 5 0.53) and
those with onset between ages 11 and 18 years decreased
from 38 to 24% (P 5 0.06) (Fig. 2B).
There was a signiﬁcant increase over time of other HLA
genotypes. Patients without HLA-DR3 or -DR4 (DRX/X)
increased in the T1DGC population from 6.5 to 10% (P 5
0.003). HLA DR4/4 and 4/X as well as DR3/3 and 3/X also
FIG. 1. Percent HLA-DR3/4-DQB1*0302 in T1DGC (A) and BDC (B) new onsets at age <18 years by decades (1965–2008).
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(Fig. 3A). In the BDC population, the trend was similar
with an increase in DRX/X from 8% between 1965–84 to
13% in 1985–2008 (P 5 0.08) (Fig. 3B).
Linear regression performed in T1DGC subjects with
onset age #5 years showed an overall linear decrease of HLA-
DR3/4-DQB1*0302 genotype over time (P 5 0.007, R2 5
0.33). However, when analyzing HLA-DR3/4-DQB1*0302
genotype in 2-year interval periods, we found a signiﬁcant
decrease in percent DR3/4 in the mid 1980s in subjects
with onset age #5 years (P 5 0.0001) (Fig. 4). We sampled
the data 20,000 times with replacement using bootstrap and
found a signiﬁcant difference between those time points
(before and after 1985), although this decrease could also
have happened in the early 1990s.
We performed the same analyses in Caucasians only
and found overall very similar results (Supplementary
Figs. 1–4).
DISCUSSION
This study conﬁrms that the highest risk HLA-DR3/
4-DQB1*0302 genotype has been decreasing in new onset
type 1 diabetic subjects in more recent decades. This
ﬁnding is consistent with several important smaller studies
reporting a similar decrease in the percent DR3/4 (8,12–
14), although some studies have not found any temporal
changes in HLA genotypes (17). This is the largest study so
far with HLA information on new onset subjects over
a period of 40 years; other studies have mainly compared
two time periods.
Previous studies have mainly selected populations from
one geographic region for HLA analysis, whereas the
T1DGC includes multiple populations and large numbers
of type 1 diabetic patients over many years. The T1DGC
data suggests that the change in high-risk HLA frequency
can be more precipitous than previously thought.
A stepwise decrease in percent DR3/4 would suggest
a relatively acute environmental change with an increase
of disease penetrance in individuals with lower-risk HLA
genotypes and/or a lower disease penetrance in subjects
with high-risk genotypes. We hypothesize that disease
penetrance might be increasing for both DR3/4 and non-
DR3/4 genotypes, but with the much larger population
proportion of non-DR3/4 individuals, the percentage DR3/4
decreases as the incidence of type 1 diabetes is increasing.
Multiple environmental changes over the past few decades
have been discussed as factors that might relate to the
increasing incidence of diabetes, including exposure to
infections in early life (enteroviruses) or decreasing fre-
quency of infections (hygiene hypothesis) (18,19), eating
habits and lifestyle modiﬁcations leading to increased
obesity and insulin resistance (accelerator hypothesis)
(20,21). Most of these environmental changes are most
likely to change slowly and progressively with time.
Other factors that could inﬂuence decreasing DR3/4
frequencies over time include different methods of ascer-
tainment of type 1 diabetes or decreasing DR3/4 frequencies
FIG. 2. Percent HLA-DR3/4-DQB1*0302 in T1DGC (A) and BDC (B) type 1 diabetic subjects by age of onset over 4 decades. Age-of-onset categories:
ages <5, 6–10, and 11–18 years.
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diabetes in very young children had increased in recent
years through better ascertainment, we would expect an
increase overall in DR3/4 frequency because subjects with
younger age of onset are those with the highest per-
centage of DR3/4. Percentage of DR3/4 is low in the
general Colorado population and did not change signif-
icantly over time (2.6% in 1945–1975 compared with 1.9%
in 2002–2004).
Although triggers of type 1 diabetes are still unknown, it is
clear that there is a long prodrome of islet autoimmunity
preceding the onset of type 1 diabetes, and there is growing
evidence that activation of innate immunity and inﬂam-
mation can be associated with induction of islet autoim-
munity in animal models. In rat strains with the equivalent
of high-risk class II HLA alleles, islet autoimmunity leading
to diabetes can be induced by infection with Kilham rat vi-
rus or even injections of poly-IC that induces interferon-a.
In the Kilham infectious model, ﬁve injections of dexa-
methasone, beginning on the day of infection, completely
blocks diabetes. Strikingly, a single dose of dexamethasone
was sufﬁcient to prevent islet destruction (22). This raises
the possibility that targeting innate immune pathways at the
initiation of islet autoimmunity may be a useful strategy for
disease prevention.
Because so many environmental factors have changed
in the last 4 decades, it would be helpful to narrow down
the time frame of change for environmental exposures. For
instance in the 1980s, given association with Reyes syn-
drome, aspirin therapy in children was acutely stopped in
many countries including the U.S. with substitution of
acetaminophen. Type 1 diabetes is not the only immune-
mediated disease with an increasing incidence rate, and
it has been suggested that changing anti-inﬂammatory
therapy in children may relate to increasing incidence of
asthma. There is epidemiological evidence that the use of
acetaminophen may increase the risk of developing asthma
(23) as well as rhinoconjunctivitis and eczema (24). Larger
studies are needed to conﬁrm the apparent stepwise chang-
ing pattern of genetic risk; if conﬁrmed, this observation may
help deﬁne critical environmental determinants of type 1
diabetes and eventually have direct bearing on therapies
to prevent islet autoimmunity.
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